Answers are grounded in this paper and cite their sources.
Pyrimidine-fused heterocyclic compounds exhibit pharmacological activity, including anti-diabetic and antibacterial, antifungal properties. This study involves the design and synthesis of pyrimidine-fused heterocyclic compounds in conjunction with ethylene glycol and TBAB. The synthesized compounds were then evaluated for their ability to inhibit the α-glucosidase enzyme and bacterial growth, aiming to reduce the consequences of diabetic mellitus (DM) and microbial infections. Antimicrobial assessments indicated that Compound VS9 exhibited efficacy against all four tested organisms: Escherichia coli, Bacillus cereus, Klebsiella pneumoniae, and Staphylococcus epidermidis. The test compounds VS9 and VS1 exhibited α-glucosidase inhibition with IC50 values of 166.52 nmol and 249.24 nmol, respectively. In silico studies, the molecule VS3 had the most favorable docking energy of −8.3 kcal/mol. Moreover, computational evaluations of drug likeness, ADME, and toxicity were conducted on the compounds, indicating that these chemical exhibits drug-like properties and possesses favorable ADME and toxicity profiles. • The multicomponent two step synthesis have cost cutting, shorter reaction time, scalable and reproducing the reaction with high yields.
No takes yet. Share an insight, caveat, or question.
Mallidi et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: